{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:32:21Z","timestamp":1789687941123,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.cct.2025.107843","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T11:27:20Z","timestamp":1739014040000},"page":"107843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 studies"],"prefix":"10.1016","volume":"151","author":[{"given":"Kenneth G.","family":"Saag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-yuan","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Fu","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Nuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Perez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William B.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hariri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younghwan","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cct.2025.107843_bb0005","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1001\/jama.2023.26640","article-title":"Serum urate and recurrent gout","volume":"331","author":"McCormick","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2025.107843_bb0010","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3899\/jrheum.160452","article-title":"Serum uric acid and the risk of incident and recurrent gout: a systematic review","volume":"44","author":"Shiozawa","year":"2017","journal-title":"J. Rheumatol."},{"issue":"2","key":"10.1016\/j.cct.2025.107843_bb0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41584-021-00725-9","article-title":"Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care","volume":"18","author":"Choi","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"issue":"4","key":"10.1016\/j.cct.2025.107843_bb0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1759720X16646703","article-title":"Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications","volume":"8","author":"Sattui","year":"2016","journal-title":"Ther. Adv. Musculoskelet Dis."},{"issue":"10","key":"10.1016\/j.cct.2025.107843_bb0025","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/art.39254","article-title":"Gout classification criteria. An American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"67","author":"Neogi","year":"2015","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.cct.2025.107843_bb0030","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/art.39684","article-title":"A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout","volume":"68","author":"Poiley","year":"2016","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cct.2025.107843_bb0035","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10264","key":"10.1016\/j.cct.2025.107843_bb0040","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2025.107843_bb0045","author":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)"},{"issue":"4S","key":"10.1016\/j.cct.2025.107843_bb0050","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int."},{"issue":"19","key":"10.1016\/j.cct.2025.107843_bb0055","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.cct.2025.107843_bb0060","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41584-022-00804-5","article-title":"When underlying biology threatens the randomization principle - initial gout flares of urate-lowering therapy","volume":"18","author":"Choi","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.cct.2025.107843_bb0065","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cct.2025.107843_bb0070","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res. Ther."},{"issue":"12","key":"10.1016\/j.cct.2025.107843_bb0075","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J. Rheumatol."},{"issue":"10","key":"10.1016\/j.cct.2025.107843_bb0080","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.cct.2025.107843_bb0085","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.cct.2025.107843_bb0090","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"American College of Rheumatology guidelines for management of gout. Part 1. Therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res."},{"issue":"10","key":"10.1016\/j.cct.2025.107843_bb0095","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"American College of Rheumatology guidelines for management of gout. Part 2. Therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res."},{"issue":"3","key":"10.1016\/j.cct.2025.107843_bb0100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3109\/00365515309094197","article-title":"Enzymatic determination of uric acid; with detailed directions","volume":"5","author":"Praetorius","year":"1953","journal-title":"Scand. J. Clin. Lab. Invest."},{"issue":"6","key":"10.1016\/j.cct.2025.107843_bb0105","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.41247","article-title":"2020 American College of Rheumatology Guideline for the Management of Gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Rhuem"},{"issue":"5","key":"10.1016\/j.cct.2025.107843_bb0110","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/art.33483","article-title":"Developing a provisional definition of flare in patients with established gout","volume":"64","author":"Gaffo","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.cct.2025.107843_bb0115","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/art.40381","article-title":"Brief report: validation of a definition of flare in patients with established gout","volume":"70","author":"Gaffo","year":"2018","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cct.2025.107843_bb0120","series-title":"Guideline on clinical investigation of medicinal products for the treatment of gout. EMA\/CHMP\/774470\/2018","author":"EMA","year":"2019"},{"key":"10.1016\/j.cct.2025.107843_bb0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.cct.2025.107843_bb0130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M16-0570","article-title":"Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann. Intern. Med."},{"issue":"10156","key":"10.1016\/j.cct.2025.107843_bb0135","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomized controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2025.107843_bb0140","author":"Zyloprim (allopurinol) Tablet for Oral Use Prescribing Information"},{"key":"10.1016\/j.cct.2025.107843_bb0145","author":"Zyloric (allopurinol) Tablet Summary of Product Characteristics"},{"issue":"1","key":"10.1016\/j.cct.2025.107843_bb0150","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13075-015-0624-3","article-title":"Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort","volume":"17","author":"Singh","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"10.1016\/j.cct.2025.107843_bb0155","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.cct.2025.107843_bb0160","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100028","article-title":"Comparative effectiveness of allopurinol and febuxostat in gout management","volume":"1","author":"O\u2019Dell","year":"2022","journal-title":"NEJM Evid."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425000370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425000370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T11:37:13Z","timestamp":1760787433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714425000370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":32,"alternative-id":["S1551714425000370"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2025.107843","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 studies","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2025.107843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107843"}}